Liatsikos Evangelos N, Georgiopoulos Loannis, Kallidonis Panagiotis, Stolzenburg Jens-Uwe
Department of Urology, University of Patras, Greece.
Indian J Urol. 2012 Jan;28(1):71-5. doi: 10.4103/0970-1591.94961.
To perform a survey of the current state of laparoendoscopic single-site surgery (LESS) and its implementation in the treatment of malignant disease of the urinary tract. Although it is a recent development in the field of laparoscopic surgery with still unproven long-term results, LESS may prove to be more commonly performed in the coming years while managing urologic cancer patients.
A PubMed search was conducted using the key words laparoendoscopic single-site surgery, LESS, urologic cancer. Relevant articles were reviewed for data on the management of urologic malignancy with LESS.
The first articles describing LESS for urologic cancers were published in 2007. Since then, published experience with this technique has increased. LESS has been implemented as an alternative to conventional laparoscopic surgery and open surgery for the treatment of major urologic cancers. The proposed advantages of LESS are the aesthetic benefit of a single incision and a quicker and less painful recovery. Disadvantages are the lack of instrument triangulation, instrument clashing and the steeper learning curve. As this is a fairly recent technical innovation, long-term functional and oncological results for LESS have not yet been published.
LESS is a novel technical advance over conventional laparoscopic surgery, and it can be successfully used in the treatment of patients with urologic cancers. Published data support the feasibility and safety of LESS interventions for major urologic cancers, and newer data may assist in finding LESS's ultimate position among therapeutic options for patients with urologic malignancies.
对腹腔镜单孔手术（LESS）的现状及其在泌尿系统恶性疾病治疗中的应用进行调查。尽管LESS是腹腔镜手术领域的一项新进展，其长期效果尚未得到证实，但在未来几年治疗泌尿系统癌症患者时，LESS可能会得到更广泛的应用。
使用关键词“laparoendoscopic single-site surgery”（腹腔镜单孔手术）、“LESS”、“urologic cancer”（泌尿系统癌症）在PubMed上进行检索。对相关文章进行综述，以获取关于LESS治疗泌尿系统恶性肿瘤的数据。
2007年发表了首批描述LESS用于泌尿系统癌症的文章。从那时起，关于这项技术的已发表经验有所增加。LESS已被用作治疗主要泌尿系统癌症的传统腹腔镜手术和开放手术的替代方法。LESS的潜在优势是单一切口的美学效果以及更快、疼痛更少的恢复。缺点是缺乏器械三角定位、器械碰撞以及学习曲线更陡峭。由于这是一项相当新的技术创新，LESS的长期功能和肿瘤学结果尚未发表。
LESS是相对于传统腹腔镜手术的一项新技术进展，可成功用于治疗泌尿系统癌症患者。已发表的数据支持LESS干预治疗主要泌尿系统癌症的可行性和安全性，新的数据可能有助于确定LESS在泌尿系统恶性肿瘤患者治疗选择中的最终地位。
